CDC Issues Recommendations for a New Pneumococcal Conjugate Vaccine

The new 13-valent pneumococcal conjugate vaccine provides expanded serotype coverage for infants and young children.

Target Population: Infectious diseases specialists, as well as physicians, nurses, and public health workers who care for children

Sponsoring Organization: CDC

Type: Recommendations of the Advisory Committee on Immunization Practices. This report is consistent with recommendations by the American Academy of Pediatrics Committee on Infectious Diseases.

Key Points: In February 2000, a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (Prevnar [PCV7]) was licensed for infants and young children in the U.S. Subsequently, the rates of pneumococcal sepsis and meningitis in children fell, but infections caused by nonvaccine serotypes have persisted, and the prevalence of nonvaccine serotypes may be increasing. On February 24, 2010, a 13-…

Author

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

CDC Issues Recommendations for a New Pneumococcal Conjugate Vaccine

Topics

Author